AU Patent

AU2013259267A1 — Treating cancer with Hsp90 inhibitory compounds

Assigned to Synta Phamaceuticals Corp · Expires 2014-11-06 · 12y expired

What this patent protects

A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acce…

USPTO Abstract

A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013259267A1
Jurisdiction
AU
Classification
—
Expires
2014-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Synta Phamaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.